BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.160
-0.340 (-13.60%)
Mar 9, 2026, 2:05 PM EDT - Market open
BioNexus Gene Lab Revenue
BioNexus Gene Lab had revenue of $2.54M in the quarter ending September 30, 2025, a decrease of -3.29%. This brings the company's revenue in the last twelve months to $9.47M, up 2.22% year-over-year. In the year 2024, BioNexus Gene Lab had annual revenue of $9.51M, down -2.66%.
Revenue (ttm)
$9.47M
Revenue Growth
+2.22%
P/S Ratio
0.62
Revenue / Employee
$315,500
Employees
30
Market Cap
5.11M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Core Molding Technologies | 261.62M |
| Aemetis | 201.32M |
| FutureFuel | 137.41M |
| Northern Technologies International | 86.20M |
| Flexible Solutions International | 38.56M |
| CN Energy Group. | 35.57M |
| J-Star Holding | 20.05M |
| Bon Natural Life | 18.67M |
BGLC News
- 14 days ago - BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman - GlobeNewsWire
- 5 weeks ago - BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market - GlobeNewsWire
- 3 months ago - BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ - GlobeNewsWire
- 3 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization - GlobeNewsWire
- 3 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - GlobeNewsWire
- 4 months ago - BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities - GlobeNewsWire
- 5 months ago - BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. - GlobeNewsWire